Research programme: autoimmune disorder therapeutics - Bristol-Myers Squibb/ Novo Nordisk
Latest Information Update: 22 Apr 2015
At a glance
- Originator Novo Nordisk
- Developer Bristol-Myers Squibb; Novo Nordisk
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders